Needham Maintains Buy on Globus Medical, Lowers Price Target to $100
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $117 to $100.
Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $117 to $100.